Jiangsu Kangning Jierui Biopharmaceutical

Alphamab Oncology is a leading clinical-stage biopharmaceutical company in China focused on developing innovative multi-functional biologics for cancer treatment. The company utilizes its proprietary protein engineering platforms, including the CRIB bispecific platform, to design and manufacture next-generation antibody candidates. Its flagship product, Envafolimab, is the first subcutaneous PD-L1 inhibitor approved globally, specifically for MSI-H/dMMR advanced solid tumors in China. Alphamab's robust pipeline includes advanced bispecific antibodies targeting PD-L1/CTLA-4 and HER2, as well as novel antibody-drug conjugates. With integrated capabilities from discovery to commercial-scale GMP manufacturing, the company aims to provide differentiated and affordable oncology therapies to patients worldwide.